MX2018007304A - Composiciones de interleucina-15 y sus usos. - Google Patents

Composiciones de interleucina-15 y sus usos.

Info

Publication number
MX2018007304A
MX2018007304A MX2018007304A MX2018007304A MX2018007304A MX 2018007304 A MX2018007304 A MX 2018007304A MX 2018007304 A MX2018007304 A MX 2018007304A MX 2018007304 A MX2018007304 A MX 2018007304A MX 2018007304 A MX2018007304 A MX 2018007304A
Authority
MX
Mexico
Prior art keywords
interleukin
compositions
pegylated interleukin
molecules
candidates
Prior art date
Application number
MX2018007304A
Other languages
English (en)
Inventor
Alan Mccauley Scott
Brian MUMM John
Ho CHAN Ivan
Original Assignee
Armo Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Armo Biosciences Inc filed Critical Armo Biosciences Inc
Publication of MX2018007304A publication Critical patent/MX2018007304A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

Se describen moléculas relacionadas con la interleuquina-15 pegilada y su identificación. Las moléculas de interleuquina-15 pegiladas exhiben propiedades y características que las hacen aptas para uso terapéutico. Las composiciones farmacéuticas y los métodos de uso también se describen en este documento.
MX2018007304A 2015-12-21 2016-12-15 Composiciones de interleucina-15 y sus usos. MX2018007304A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562270447P 2015-12-21 2015-12-21
PCT/US2016/067042 WO2017112528A2 (en) 2015-12-21 2016-12-15 Interleukin-15 compositions and uses thereof

Publications (1)

Publication Number Publication Date
MX2018007304A true MX2018007304A (es) 2019-03-14

Family

ID=59091160

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018007304A MX2018007304A (es) 2015-12-21 2016-12-15 Composiciones de interleucina-15 y sus usos.

Country Status (12)

Country Link
US (1) US20180360977A1 (es)
EP (1) EP3393486A4 (es)
JP (1) JP2019503348A (es)
KR (1) KR20180089516A (es)
CN (1) CN108472324A (es)
AU (1) AU2016378387A1 (es)
BR (1) BR112018012262A2 (es)
CA (1) CA3007819A1 (es)
IL (1) IL259919A (es)
MX (1) MX2018007304A (es)
WO (1) WO2017112528A2 (es)
ZA (1) ZA201803875B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2950570T3 (es) * 2017-07-25 2023-10-11 Jiangsu Hengrui Medicine Co Composición farmacéutica del complejo de proteína il-15 y usos de la misma
SG11202007728QA (en) * 2018-02-26 2020-09-29 Synthorx Inc Il-15 conjugates and uses thereof
WO2019245817A1 (en) 2018-06-19 2019-12-26 Armo Biosciences, Inc. Compositions and methods of use of il-10 agents in conjunction with chimeric antigen receptor cell therapy
JP2022512944A (ja) * 2018-11-09 2022-02-07 ネクター セラピューティクス 別の薬理学的に活性な薬剤と組み合わせた長時間作用型インターロイキン－１５受容体作動薬
WO2020219943A1 (en) * 2019-04-26 2020-10-29 Prolynx Llc Slow-release cytokine conjugates
AU2020279534A1 (en) 2019-05-20 2021-11-11 Cytune Pharma IL-2/IL-15Rβy agonist dosing regimens for treating cancer or infectious diseases
MX2022002053A (es) * 2019-08-23 2022-03-17 Synthorx Inc Conjugados de il-15 y sus usos.
IL302313A (en) 2020-10-26 2023-06-01 Cytune Pharma IL-2/IL-15RBY agonist for the treatment of non-melanoma skin cancer
IL302321A (en) 2020-10-26 2023-06-01 Cytune Pharma IL-2/IL-15RBY agonist for the treatment of squamous cell carcinoma
CA3220418A1 (en) 2021-06-23 2022-12-29 Guy Luc Michel De Martynoff Interleukin 15 variants
EP4384204A1 (en) 2021-08-13 2024-06-19 Cytune Pharma Il-2/il-15rbetagamma agonist combination with antibody-drug conjugates for treating cancer
WO2023093826A1 (zh) * 2021-11-26 2023-06-01 杰科（天津）生物医药有限公司 一种蛋白的生产方法及其应用
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7858081B2 (en) * 2004-02-27 2010-12-28 Inserm (Institut National De La Sante Et De La Recherche Medicale) IL-15 mutants having agonists/antagonists activity
WO2006017853A2 (en) * 2004-08-11 2006-02-16 Beth Israel Deaconess Medical Center, Inc. Mutant interleukin-15-containing compositions and suppression of an immune response
AU2005335217A1 (en) * 2004-10-05 2007-02-15 Ochsner Clinic Foundation Enhancement of B cell proliferation by IL-15
MA39711A (fr) * 2014-04-03 2015-10-08 Nektar Therapeutics Conjugués d'une fraction d'il-15 et d'un polymère
JP2017536098A (ja) * 2014-10-14 2017-12-07 アルモ・バイオサイエンシーズ・インコーポレイテッド インターロイキン−１５組成物及びその使用

Also Published As

Publication number Publication date
AU2016378387A1 (en) 2018-07-05
EP3393486A4 (en) 2019-09-11
CN108472324A (zh) 2018-08-31
BR112018012262A2 (pt) 2018-12-04
IL259919A (en) 2018-07-31
WO2017112528A2 (en) 2017-06-29
WO2017112528A3 (en) 2017-08-31
KR20180089516A (ko) 2018-08-08
EP3393486A2 (en) 2018-10-31
CA3007819A1 (en) 2017-06-29
JP2019503348A (ja) 2019-02-07
ZA201803875B (en) 2019-08-28
US20180360977A1 (en) 2018-12-20

Similar Documents

Publication Publication Date Title
MX2018007304A (es) Composiciones de interleucina-15 y sus usos.
PH12018500950A1 (en) Subcutaneous formulations of anti-cd38 antibodies and their uses
ZA202107931B (en) Anti-tau antibodies and methods of use
MX2017004838A (es) Composiciones de interleucina-15 y usos de estas.
MD3209310T2 (ro) Compoziții care conțin tulpini bacteriene
MD3209381T2 (ro) Compoziții care conțin tulpini bacteriene
GEP20217239B (en) Pharmaceutical composition
MX2018009750A (es) Composiciones potenciadoras de vcn y métodos para su uso.
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
MX2019004690A (es) Constructos de anticuerpos.
MX2017004808A (es) Combinaciones que comprenden siponimod y laquinimod para el tratamiento de la esclerosis multiple.
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
GEP20217240B (en) Pharmaceutical composition
PH12017502028A1 (en) Vortioxetine pyroglutamate
MX2017014456A (es) Usos terapeuticos de l-4-cloroquinurenina.
MX2017012596A (es) Una composicion farmaceutica y el uso de la misma.
MX2017000862A (es) Formulacion de factor viii.
PH12017500348B1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
MX2016016233A (es) Anticuerpos anti-lgr5 y sus usos.
PH12016501838A1 (en) Compounds and their methods of use
MX2018011219A (es) Trail diseñado por ingenieria para terapia de cancer.
MX2017003949A (es) Derivados peptidicos novedosos y sus usos.
AU201712657S (en) Flask